Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 2

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 2Breast 2

Conditions

Melanoma 2Breast Neoplasms 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of the Lung 1Neoplasm Metastasis 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × CR011-vcMMAE × Clear all
NCT02713828 2019-07-16

PrE0504

PrECOG, LLC.

Phase 1/2 Terminated
13 enrolled 12 charts

Squamous Cell Carcinoma of the Lung

NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT00412828 2015-02-19

A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma

Celldex Therapeutics

Phase 1/2 Completed
117 enrolled
Dermatologic

Melanoma

NCT00704158 2015-02-19

Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer

Celldex Therapeutics

Phase 1/2 Completed
42 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡